Biggest News Aggregation in the World
📰 Looking Statement News

Page 21 - Looking Statement News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.

Merck Animal Health Expands Voluntary Recall with Four Additional Lots of BANAMINE® / BANAMINE®-S (flunixin meglumine injection) in the U.S., Due to Presence of Particulate Matter

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), is voluntarily recalling four additional batches of BANAMINE® / BANAMINE®-S (flunixin meglumine injection) 50 mg/mL in the United States, used for i
United States Tom Schad Statement Of Merck Co Inc Company Announcement Merck Co Inc Drug Administration
Source: fda.gov

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

Application based on clinically meaningful results from the Phase 3 STELLAR trial If approved, sotatercept would be the first in its class, bringing a novel approach to address a rare and...
United States Joerg Koglin Statement Of Merck Co Inc Merck Co Inc European Medicines Agency Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus...
New Zealand United States Eli Lilly Corina Dutcus Gregory Lubiniecki Statement Of Merck Co Inc

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

First Phase 3 results for the KEYTRUDA® and Padcev® combination showed a statistically significant and clinically meaningful improvement in OS, PFS and key secondary endpoint of overall response...
United States Eliav Barr Seagen Padcev Agensys Inc Statement Of Merck Co Inc Exchange Commission

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Acceptance based on results from the Phase 3 KEYNOTE-A18 trial, which showed a statistically significant and clinically meaningful improvement in progression-free survival in these patients ...
United States Gursel Aktan Drug Administration Statement Of Merck Co Inc Merck Research Laboratories Merck Co Inc

Aligned Risk Analytics Bundles Zerify Meet into New Cyber Offer for Financial and Legal Industries Throughout Central, South America & Mexico

EDISON, N.J., Sept. 20, 2023 -- Zerify Inc., , the 22-year-old cybersecurity company focused on securing communications, collaboration and confidential data announced today that Aligned Risk...
United States Michael Hollingsworth Markl Kay Globenewswire Inc Zerify Inc Aligned Risk Analytics

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science